Summary: Non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) are less responsive to radiotherapy than the more common pediatric soft tissue sarcomas, rhabdomyosarcoma and Ewing sarcoma of soft tissue. However, radiation therapy does play an important role in the treatment of NRSTS, including synovial sarcoma. Little data exists regarding the behavior or treatment of these tumors in adolescents and young adults compared to older populations. Limb-preservation with adjuvant radiation thereby is standard. There is a greater incentive to reduce long-term complications of radiation in younger patients and thus smaller margins, lower doses, and conformal techniques should be considered. Results of anticipated cooperative group studies promise to guide future therapy for the various types of NRSTS.
B
ecause synovial sarcoma is a rare diagnosis, this tumor has been lumped together with all of the other nonrhabdomyosarcoma soft tissue sarcomas (NRSTS) in clinical trials of radiotherapy. Furthermore, most of the useful data regarding radiation treatment of NRSTS are derived from studies limited to adults. Unlike rhabdomyosarcoma and Ewing sarcoma, where radiotherapy can be used instead of surgery, local control with radiotherapy alone for other types of unresectable soft tissue sarcomas is reported to be no higher than 25% to 30%.
The current standard for high-grade soft tissue sarcomas is limb-preserving resection, when possible, in conjunction with radiotherapy. In a well-known prospective randomized trial from the National Cancer Institute (NCI), this approach was shown to produce disease-free and overall survival rates similar to those achieved with amputation. 1 Subsequently, the NCI has reported another prospective randomized trial comparing limb-preserving surgery with or without postoperative radiation. Radiotherapy was shown to significantly decrease the risk of local relapse for patients with both high-grade and low-grade sarcomas.
2 Radiation therapy did not affect overall survival in this trial. There are single-institution series of highly selected patients indicating that some patients with high-grade tumors less than 5 cm in widest diameter may have excellent local control with wide resection alone. 3, 4 At this time, no histology-specific guidelines exist for the use of radiotherapy in NRSTS. It is generally believed, though not proven, that synovial sarcoma may be more sensitive to radiotherapy than other types of NRSTS, based on its improved responsiveness to chemotherapy. Adjuvant radiotherapy has been associated with improved survival for patients with synovial sarcoma. 5 Nonetheless, maximal surgical resection is still recommended. It is hoped that the development of multiinstitutional clinical trials will allow investigators to gain more understanding about the relationship between specific rare histologies and radiation therapy.
RADIATION PLANNING
The radiation target volume consists of the tumor volume at diagnosis plus a margin. While a standard sarcoma margin in adults is 5 cm, an effort is made in younger patients to reduce the margin to 2 cm so that more normal tissue is spared. Traditionally, the entire operative bed and all scars have been included in the initial treatment volume. This concept has recently been challenged because of the excellent results achieved with brachytherapy, where all of these areas are not necessarily included. In the 1980s, the Pediatric Oncology Group randomized patients with Ewing sarcoma to involved-field (tumor plus a 2-cm margin) versus whole-bone or whole-muscle-bundle radiotherapy. With recently reported mature results, there was no difference in event-free survival between the groups. 6 It is preferred not to irradiate across a joint space when possible. It is also imperative that a strip of normal tissue be spared when treating an extremity, since circumferential radiation could result in severe lymphedema.
In adults, radiation doses of 63 to 70 Gy are typically used for adjuvant treatment of NRSTS. While these doses may be reasonable for older teenagers and young adults, there is concern that such high doses will cause significant morbidity in younger patients. There are no reliable data to confirm what dose is adequate for various histologies and clinical situations. Some rhabdomyosarcoma and Ewing sarcoma trials that include NRSTS have used doses as low as 40 to 50 Gy. The Children's Oncology Group NRSTS Committee has proposed a preoperative dose of 50.4 Gy or a postoperative dose of 55.8 Gy. Outside of an investigational trial, factors such as the patient's age, tumor histology and site, as well as surgical margin status, should be considered when choosing a dose.
TIMING OF RADIOTHERAPY
The timing of radiation treatment depends on a number of factors, including histologic diagnosis, tumor location, extent of disease, and details of surgery and/or chemotherapy. Postoperative radiation therapy is most commonly used and should begin as soon as adequate wound healing has been achieved; this is usually at 3 to 6 weeks after surgery. Any further delay may increase the risk of a local recurrence. Radiation therapy should not be given concurrently with doxorubicin chemotherapy because of the severe radiosensitizing effect on normal tissues such as skin.
Preoperative radiotherapy may be given with or without chemotherapy in cases where shrinking the tumor may significantly improve the possibility or quality of resection. Aside from potentially increasing resectability, preoperative radiation may decrease the risk of tumor contamination at the time of surgery. Preoperative radiation often allows for smaller radiotherapy treatment fields, especially if extensive surgery is planned. A lower dose of radiation may theoretically be given before surgery, since the biologic effectiveness is expected to be higher in the well-oxygenated intact tumor than in a hypoxic tumor bed. Potential disadvantages of preoperative radiation therapy are the delay in surgical resection, increased risk of wound healing complications, and less information on tumor extent and pathology. Nonetheless, long-term function appears to be better in patients receiving preoperative therapy.
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BRACHYTHERAPY
In experienced hands, brachytherapy can be an excellent postoperative treatment of patients with soft tissue sarcomas. In a prospective randomized trial, adjuvant brachytherapy was associated with a dramatic improvement in local control of high-grade lesions (89% with brachytherapy vs. 66% with no radiation). 9 A second study from the same center showed that external-beam radiotherapy should be added to brachytherapy for tumors that were resected with involved surgical margins. Local control was 90% with external beam plus brachytherapy versus 59% with brachytherapy alone. 10 
NEW TECHNOLOGIES
Intensity-modulated radiation therapy and proton beam therapy may be used in sarcomas in an effort to decrease the late side effects of radiation. Selective avoidance of critical normal tissues near the tumor may be achieved with these modalities, providing a dramatic improvement in long-term outcome for young patients. For instance, in an adolescent with a tumor surrounding a growing bone, the bone dose can often be reduced so that the bone can attain normal growth. Patients with tumors in almost all anatomic sites can potentially benefit from this advanced technology.
SIDE EFFECTS Acute Side Effects
External beam radiotherapy is typically given once daily, 5 days per week. A course of radiation for sarcoma may require 6 to 7 weeks to complete, depending on the total dose required. Acute side effects of treatment generally begin after the first 2 weeks and increase as treatment continues. Most patients report fatigue during radiation, and the majority develop a grade 1 to 3 skin reaction, especially with extremity treatment. Provided that adequate wound healing is achieved before beginning radiation, it is uncommon for wound dehiscence to occur. Radiation suppresses blood counts only if large volumes of bone marrow are included in the field, as in the case of large pelvic tumors. Other acute side effects are less common and depend on the anatomic site.
Long-Term Side Effects
The long-term complications of radiation therapy in adolescents and young adults can be significant and potentially debilitating, depending on the site treated and the dose and technique used. It is the responsibility of the radiation oncologist to do everything possible to minimize the risk of longterm side effects. Months to years after receiving radiation therapy, patients may experience muscle fibrosis. This may be asymptomatic or in more severe cases may inhibit function. Stretching exercises are recommended to combat this problem. In a prepubescent child, radiation doses greater than 20 to 25 Gy can lead to problems with bone growth. In older teens and young adults, high doses can weaken bones or cause joint dysfunction. Only in rare cases does this lead to a serious complication such as fracture or the need for joint replacement. Edema distal to the irradiated site in an extremity may occur as a result of radiation. This risk depends on the extent of surgery as well as the amount of soft tissue that is spared.
Young patients have a higher risk of a second malignancy than older adults, typically more than 10 years after radiation. A large study from the Registry of Childhood Tumors in Britain showed that the rate of secondary bone cancer after treatment of all childhood cancers was less than 1%. For those treated for Ewing sarcoma the risk was 5.4%, and the risk of second cancer increased linearly with increasing radiation dose.
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CONCLUSIONS
Radiation therapy plays an important adjuvant role in the multimodality management for many patients with synovial sarcoma and other NRSTS. Limb-sparing surgery coupled with radiotherapy results in survival rates equivalent to amputation. Preoperative radiotherapy may be considered for sarcomas that are large or difficult to resect, and brachytherapy can be used in appropriate cases. Recent technological advances in radiation delivery hold the promise of fewer normal tissue complications. Ongoing study of the unique characteristics of individual NRSTS histologies, including synovial sarcoma, may allow for more tailored therapy in the future. 
